FibroBiologics, Inc. (FBLG) shareholders
Close on Nov 17, 2026Market cap $6.00MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Pete O'Heeron | 6,951,459 | 18.20% | 13G (passive) | Jan 31, 2024 |
| Mike Newlin | 2,134,853 | 5.58% | 13G (passive) | Aug 9, 2024 |
| Steven Boyd Joint filing with Armistice Capital, LLC (9.99%) | 738,977 | 9.99% | 13G (passive) | Jun 30, 2026 |
| Hamid Khoja | 630,009 | 7.50% | 13D (active) | Sep 15, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FBLG | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Cascade Financial Partners, LLC | 108,828 | 1.63% | $103.14K | +92,400 | 0.01% |
| Fund Evaluation Group, LLC | 51,794 | 0.78% | $49.09K | – | 0.00% |
| Geode Capital Management, LLC | 30,299 | 0.46% | $28.72K | +690 | 0.00% |
| Vanguard Capital Management LLC | 27,769 | 0.42% | $26.33K | −39,896 | 0.00% |
| Qube Research & Technologies Ltd | 24,313 | 0.37% | $23.04K | New | 0.00% |
| BlackRock, Inc. | 18,238 | 0.27% | $17.28K | −6,409 | 0.00% |
| Barclays PLC | 7,243 | 0.11% | $6.86K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 6,380 | 0.10% | $6.05K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 4,728 | 0.07% | $4.48K | +4,268 | 0.00% |
| Osaic Holdings, Inc. | 2,404 | 0.04% | $2.28K | +2,250 | 0.00% |
| Royal Bank of Canada | 1,522 | 0.02% | $1.00K | +1,336 | 0.00% |
| UBS Group AG | 1,073 | 0.02% | $1.02K | −4,648 | 0.00% |
| Islay Capital Management, LLC | 169 | 0.00% | $160 | – | 0.00% |
| Grove Bank & Trust | 100 | 0.00% | $95 | New | 0.00% |
| Bnp Paribas Arbitrage, Snc | 64 | 0.00% | $61 | −2 | 0.00% |
| Allworth Financial LP | 13 | 0.00% | $13 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 16 | 0M | 4.3% | 3 / 5 | 4 / 4 | 0M | 0M |
| Q1 2026 | 17 | 0M | 3.3% | 17 / 0 | 0 / 0 | 0M | 0M |
| Q3 2025 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q2 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
5 funds held FBLG in Q2 2026, 52% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of FBLG | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 27,769 | 0.42% | $26.32K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 19,544 | 0.29% | $22.67K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 2,571 | 0.04% | $2.98K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,266 | 0.03% | $2.63K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 1,099 | 0.02% | $1.27K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Pete O'Heeron | CHIEF EXECUTIVE OFFICER, Director | 5,958,147 | 89.49% | May 4, 2026 |
| Hamid Khoja | Chief Scientific Officer | 301,571 | 4.53% | Sep 15, 2026 |
| Jason Davis | Chief Financial Officer | 70,000 | 1.05% | May 4, 2026 |
| Ruben A. Garcia | General Counsel | 180,000 | 2.70% | May 4, 2026 |
| Leigh Steinberg | Director | – | – | Sep 1, 2026 |
| Kathleen Hallisey Rubins | Director | – | – | Jul 16, 2026 |
| Matthew Link | Director | 7,500 | 0.11% | Jun 23, 2026 |
| Victoria Ninon Olivia Niklas | Director | 7,500 | 0.11% | Jun 23, 2026 |
| Robert E. Hoffman | Director | 7,500 | 0.11% | Jun 23, 2026 |
| Richard C. Cilento Jr. | Director | 93,225 | 1.40% | Jun 23, 2026 |
| Stacy Ann Coen | Director | 7,500 | 0.11% | Jun 12, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Hamid Khoja Chief Scientific Officer | Sep 15, 2026 | Award | +298,508 | $1.68 | $501.49K | 301,571 |
| Hamid Khoja Chief Scientific Officer | Mar 4, 2026 | Buy | +30,000 | $0.38 | $11.40K | 61,250 |
| Pete O'Heeron CHIEF EXECUTIVE OFFICER, Director | Mar 4, 2026 | Buy | +15,872 | $0.38 | $6.03K | 5,958,147 |
| Pete O'Heeron CHIEF EXECUTIVE OFFICER, Director | Mar 3, 2026 | Buy | +18,200 | $0.41 | $7.46K | 5,942,275 |
| Pete O'Heeron CHIEF EXECUTIVE OFFICER, Director | Mar 2, 2026 | Buy | +17,428 | $0.35 | $6.10K | 5,924,075 |
| Jason Davis Chief Financial Officer | Mar 2, 2026 | Buy | +70,000 | $0.41 | $28.70K | 70,000 |
| Ruben A. Garcia General Counsel | Feb 27, 2026 | Buy | +40,000 | $0.33 | $13.20K | 180,000 |
| Ruben A. Garcia General Counsel | Dec 11, 2025 | Buy | +140,000 | $0.34 | $47.60K | 140,000 |
| Hamid Khoja Chief Scientific Officer | May 27, 2025 | Buy | +20,000 | $0.84 | $16.80K | 31,250 |
| Pete O'Heeron Chief Executive Officer, Director | Dec 9, 2024 | Gift | −100,000 | – | – | 5,906,647 |
| Pete O'Heeron Chief Executive Officer, Director | Dec 3, 2024 | Gift | −50,000 | – | – | 6,006,647 |
| Pete O'Heeron Chief Executive Officer, Director | Aug 12, 2024 | Buy | +8,500 | $1.91 | $16.24K | 6,056,647 |
| Hamid Khoja Chief Scientific Officer | Aug 12, 2024 | Buy | +10,000 | $1.90 | $19.00K | 11,250 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of FibroBiologics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 29,056 shares on Sep 2, 2026 over the last 90 days.
See a number that looks wrong?